Filtered By:
Source: NIH OTT Licensing Opportunities
Condition: Multiple Sclerosis

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 6 results found since Jan 2013.

Use of E-Selectin Tolerization as Treatment for Immunological and Vascular-Related Disorders
This technology relates to the mucosal delivery (e.g. intranasal) of an E-selectin fragment as a tolerization agent for the prevention and treatment of immunological and vascular-related disorders, including stroke and multiple sclerosis (MS) as well as rare or orphan diseases involving vascular modulated disorders. E-selectin is an adhesion molecule that is expressed on endothelial cells lining blood vessels in response to certain localized cytokines, making the endothelial surface pro-coagulant, pro-inflammatory and/or immunoreactive. Such changes on the endothelial surface have been linked to the development of vascula...
Source: NIH OTT Licensing Opportunities - April 1, 2001 Category: Research Authors: admin Source Type: research

Novel Magnetic Resonance Spectroscopy (MRS) Technique to Quantify Brain Metabolites
With respect to quantification of metabolites in the brain, conventional methods of magnetic resonance spectroscopy (MRS) yield results that are highly variable and highly dependent on the sequence type being applied. This invention describes a novel MRS technique that involves preparing longitudinal steady states at different flip angles using trains of RF pulses interspersed with field gradients to quantify metabolites. The method allows quantification of metabolites and their relaxation rates under specified parameters, which may create new ways of analyzing and interpreting tissue properties or identifying and characte...
Source: NIH OTT Licensing Opportunities - May 23, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Isotropic Generalized Diffusion Tensor MRI
Scientists at the Eunice Kennedy Shriver National Institute for Child Health and Human Development (NICHD) have developed a method implemented as pulse sequences and software to be used with magnetic resonance imaging (MRI) scanners and systems. This technology is available for licensing and commercial development. The method allows for measuring and mapping features of the bulk or average apparent diffusion coefficient (ADC) of water in tissue – aiding in stroke diagnosis and cancer therapy assessment. The pulse sequences and software enable MRI scanners to yield diffusion weighted images (DWI) that are orientationally ...
Source: NIH OTT Licensing Opportunities - August 16, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research

Novel Derivatives of Docosahexaenoylethanolamide as Therapeutics for Neuronal Disorders
This technology provides derivatives of Docosahexaenoylethanolamide (synaptamide or DEA) which have increased potency and hydrolysis resistance as compared to DEA (structures of these derivatives are available upon request), as well as methods of using these derivatives to promote neurogenesis, neurite growth, and/or synaptogenesis. Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid that accumulates in the brain during development, has been shown to play a key role in learning and memory development. Studies have also shown that DEA, a metabolite derived from DHA is very potent in accelerating neuronal growth an...
Source: NIH OTT Licensing Opportunities - January 24, 2013 Category: Research Authors: admin Source Type: research

Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis
The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple sclerosis, autism, Alzheimer ' s disease, Huntington ' s disease, Parkinson ' s disease, amyotrophic lateral sclerosis. The DEA derivatives of the invention have increased potency and hydrolysis resistance as compared to native DEA. Docosahexaenoic acid (DHA), an n-3 polyunsat...
Source: NIH OTT Licensing Opportunities - January 24, 2013 Category: Research Authors: ajoyprabhu3 Source Type: research

Thalidomide Analogs that Inhibit Inflammation and Angiogenesis
Thalidomide and its close analogs (lenalidomide and pomalidomide) are widely used to treat a variety of diseases, such as multiple myeloma and other cancers as well as the symptoms of several inflammatory disorders. However, thalidomide is known for its teratogenic adverse effects when first clinically introduced in the 1950s, and is associated with drowsiness and peripheral neuropathy. Hence, there is intense interest to synthesize, identify and develop safer analogs.Researchers at the National Institute on Aging’s Drug Design and Development Section synthesized novel thalidomide analogs that demonstrate clinical potent...
Source: NIH OTT Licensing Opportunities - December 23, 2015 Category: Research Authors: admin Source Type: research